SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurex Corporation
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
449 4 0 NXCO
Emcee:  ChinuSFO Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
399 I agree with your comments and reiterate that I was impressed with the data preDr. John M. de Castro-1/16/1998
398 I respect your concern here, and I am aware that effect size diminishes with thNeuroInvestment-1/15/1998
397 I think you're being overly optimistic here. This is the same tune that I sDr. John M. de Castro-1/15/1998
396 NeuroInvestment: Sorry you had to wait for me, and perhaps others, to catch upJohn McCarthy-1/15/1998
395 1)Keep in mind that this was an interim analysis, the company remained blinded NeuroInvestment-1/15/1998
394 Giuseppe - I understand your relief in the fact that Morgan upgraded. I &quoJohn McCarthy-1/14/1998
393 Dr. De Castro, You provide some very valuable insight and you are correct in bGiuseppe Scalamogna-1/14/1998
392 For those who are interested: Since I have been receiving a fair number of emaiNeuroInvestment-1/14/1998
391 Three notes: 1) Technically, ziconotide is a specific calcium channel blocker, NeuroInvestment-1/14/1998
390 John - Cannot thank you enough. I mean it. Good god. The dreaded "E"John McCarthy-1/13/1998
389 John, the patient population is one that is either refractory or non responsiveDr. John M. de Castro-1/13/1998
388 NeuroInvestment - Thanks - was not trying to kill you with the question - justJohn McCarthy-1/13/1998
387 It largely depends on whether the FDA grants expedited status. This is not a diNeuroInvestment-1/13/1998
386 Michael - I'll leave it to others with respect to $$$, but be aware that NJohn McCarthy-1/13/1998
385 NeuroInvestment - If I thought: 98 June NDA 98 Dec ODAC 99 Mar FDA Panel WJohn McCarthy-1/13/1998
384 What is the market potential for this drug? Any reasonable price targets? MIKMichael Young-1/13/1998
383 What steps are involved in the review of the NDA and how long generally before Cody Goebel-1/13/1998
382 Phase III patient accrual is done for the neuropathic and malignant pain trialsNeuroInvestment-1/13/1998
381 John - Do you have a guess when P3 will be completed? And, would they at leasJohn McCarthy-1/13/1998
380 Yeah, NXCO reported encouraging neuropathic pain trial results biz.yahoo.com Dr. John M. de Castro-1/13/1998
379 Why the big pop up today? Any news? MikeMichael C Quesnel-1/13/1998
378 The current price reflects nothing but negative sentiment for the sector as a wNeuroInvestment-12/22/1997
377 Any news on NXCO lately? The stock is just hovering between 13 & 15. NeurChinuSFO-12/22/1997
376 Hopefully they will sell some of this stuff. I am surprised they are not goingAT7-11/18/1997
375 Corlopam gross margin should come in around 90%. How about that for a great retGiuseppe Scalamogna-11/18/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News